-
1.发明专利
公开(公告)号：JP2004049240A
公开(公告)日：2004-02-19
申请号：JP2003276312
申请日：2003-07-17
Inventor： SCHNEIDINGER BERND , MEIER THOMAS , SCHMUCK RAINER , SHAO ZHIXIN
Abstract: PROBLEM TO BE SOLVED: To provide a conjugate of alkaline phosphatase available for a quantitative determination of the alkaline phosphatase as a standard and reproducibly produced by a simple method.
SOLUTION: The conjugate of tissue non-specific alkaline phosphatase (tns-AP) and dextran in the invention is obtained by reacting a non-glycosylated tns-AP with an activated dextran in an aqueous solution , stopping the reaction, and isolating the conjugate of tns-AP and dextran from the solution.
COPYRIGHT: (C)2004,JPO-
公开(公告)号：WO02103026A2
公开(公告)日：2002-12-27
申请号：PCT/EP0205782
申请日：2002-05-27
Applicant: HOFFMANN LA ROCHE
Inventor： HOESS EVA , MEIER THOMAS , PESTLIN GABRIELE , POPP FRIEDRICH , REICHERT KLAUS , SCHMUCK RAINER , SCHNEIDINGER BERND , SEIDEL CHRISTOPH , TISCHER WILHELM
IPC: C12N15/09 , A61K38/00 , A61P31/12 , A61P31/18 , C07K14/155 , C07K14/16 , C12N1/21 , C12N15/62 , C12P21/02 , C12P21/00
CPC classification number: C07K14/005 , C07K2319/00 , C12N2740/15022 , C12N2740/16122 , C12P21/02
Abstract: A process for the production of an antifusogenic peptide of a length of about 10 to 50 amino acids in a prokaryotic host cell, characterized in that, under such conditions that inclusion bodies of said non-fusion antifusogenic peptide or said fusion peptide are formed, a) in said host cell there is expressed a nucleic acid encoding said antifusogenic peptide as a non-fusion peptide or encoding a fusion peptide of a length of about 14 to 70 amino acids consisting of said antifusogenic peptide N-terminally linked to a further peptide of a length of about 4 to 30 amino acids; b) said host cell is cultivated; c) said inclusion bodies are recovered and solubilized; d) in the case of said fusion peptide said antifusogenic peptide is cleaved off from said further peptide; and e) said antifusogenic peptide is isolated.
Abstract translation: 一种在原核宿主细胞中生产长度约10至50个氨基酸的抗融合肽的方法，其特征在于，在形成所述非融合抗融合肽或所述融合肽的包涵体的条件下， ）在所述宿主细胞中表达编码所述抗融合肽作为非融合肽或编码长度约为14至70个氨基酸的融合肽的核酸，所述融合肽由所述抗融合肽组成，所述融合肽与N-末端连接的另一个肽 长度约4至30个氨基酸; b）培养宿主细胞; c）所述包涵体被回收和溶解; d）在所述融合肽的情况下，所述抗融合肽从所述另外的肽切除; 和e）分离所述抗融合肽。
-
公开(公告)号：WO2011012270A8
公开(公告)日：2012-02-23
申请号：PCT/EP2010004523
申请日：2010-07-23
Applicant: ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , DUEFEL HARTMUT , HEINDL DIETER , HORN CARINA , MEIER THOMAS , SCHMUCK RAINER
Inventor： DUEFEL HARTMUT , HEINDL DIETER , HORN CARINA , MEIER THOMAS , SCHMUCK RAINER
IPC: C12P19/32
CPC classification number: C07H19/207 , C12P19/32
Abstract: The invention concerns the enzymatic synthesis of stable analogues of nicotinamide adenine dinucleotide NAD/NADH and nicotinamide adenine dinucleotide phosphate NADP/NADPH, the so-called "carba-NADs", i.e. analogues of NAD/NADH or NADP/NADPH, respectively, comprising a carbacyclic sugar instead of ribose.
Abstract translation: 本发明涉及烟酰胺腺嘌呤二核苷酸NAD / NADH和烟酰胺腺嘌呤二核苷酸磷酸NADP / NADPH的稳定类似物的酶合成，即所谓的“carba-NAD”，即NAD / NADH或NADP / NADPH的类似物，分别包含 碳环糖代替核糖。
-
公开(公告)号：WO02072634A3
公开(公告)日：2003-03-13
申请号：PCT/EP0201322
申请日：2002-02-08
Applicant: ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , MUELLER RAINER , THALHOFER JOHANN-PETER , REXER BERNHARD , SCHMUCK RAINER , GEIPEL FRANK , GLASER STEPHAN , SCHOEN HELMUT , MEIER THOMAS , RUDOLPH RAINER , LILIE HAUKE , SCHOTT BJOERN
Inventor： MUELLER RAINER , THALHOFER JOHANN-PETER , REXER BERNHARD , SCHMUCK RAINER , GEIPEL FRANK , GLASER STEPHAN , SCHOEN HELMUT , MEIER THOMAS , RUDOLPH RAINER , LILIE HAUKE , SCHOTT BJOERN
IPC: C12N15/09 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/12 , C12N9/58 , C12N15/55 , C07K1/113 , C12N15/70
CPC classification number: C12N9/58 , C07K2319/00 , C12Y304/21064
Abstract: The invention relates to recombinant proteinase K and to a method for producing recombinant proteinase K, which is characterised by the following steps: a) transformation of a host cell containing a recombinant nucleic acid that codes for the zymogenic precursor of the proteinase K, b) cultivation of the host cell in such a way that the zymogenic precursor of proteinase K occurs in the form of inclusion bodies in said host cell, c) isolation of the inclusion bodies and re-naturing under conditions, from which the protease part of the zymogenic precursor emerges in its natural conformation, d) activation and purification of the re-natured proteinase K.
Abstract translation: 在本发明中，重组蛋白酶K进行说明。 此外，公开了用于生产重组蛋白酶K的方法，其特点在于：a）转化的宿主细胞用重组核酸，其编码K中蛋白酶的酶原前体，b）以一种方式培养该宿主细胞，该酶原前体 通过蛋白酶K在宿主细胞“包涵体”的形式生产的，c）分离“包涵体”，和复性的条件下，其中在它们的天然构象所产生的酶原前体，D）的活化和纯化，性蛋白酶K的蛋白酶部分 ，
-
公开(公告)号：CA2750474C
公开(公告)日：2017-07-25
申请号：CA2750474
申请日：2010-02-12
Applicant: HOFFMANN LA ROCHE
Inventor： HORN CARINA , GASSLER-DIETSCHE CLAUDIA , HEINDL DIETER , HONES JOACHIM , MEIER THOMAS , SCHMUCK RAINER
IPC: C12Q1/32
Abstract: The present description concerns a method for determining an analyte as well as a diagnostic element suitable therefor, the method comprising the steps of contacting a sample containing the analyte with a diagnostic element comprising a dry reagent layer which contains a mutated glucose dehydrogenase (EC 1.1.1.47) which is specific for the analyte, and an artificial coenzyme; and determining at least one of the presence and the amount of the analyte.
-
Patent Agency Ranking
公开(公告)号：HK1205757A1
公开(公告)日：2015-12-24
申请号：HK15106269
申请日：2015-07-02
Applicant: HOFFMANN LA ROCHE
Inventor： DFEL HARTMUT , MEIER THOMAS , TACKE MICHAEL
IPC: C12N20060101
Abstract: Compositions, devices, kits and methods are disclosed for assaying glucose with a glycosylated, modified flavin adenine dinucleotide-dependent glucose dehydrogenase (FAD-GDH), variant thereof or an active fragment thereof, where at least one asparagine residue at positions N2, N168 and N346 of mature, wild-type A. oryzae FAD-GDH according to SEQ ID NO:2 is substituted by one or more amino acids not suitable for glycosylation, thereby eliminating or inactivating, respectively, a potential glycosylation site at this position.
-
公开(公告)号：PL2017352T3
公开(公告)日：2015-02-27
申请号：PL08012856
申请日：2008-07-16
Applicant: HOFFMANN LA ROCHE
Inventor： STAIB ARNULF , MEIER THOMAS , MISCHLER REINHOLD , PESCHEL HARALD , HAJNSEK MARTIN
IPC: C12Q1/00
-
公开(公告)号：ES2525317T3
公开(公告)日：2014-12-22
申请号：ES02740652
申请日：2002-05-27
Applicant: HOFFMANN LA ROCHE
Inventor： HOESS EVA , MEIER THOMAS , PESTLIN GABRIELE , POPP FRIEDRICH , REICHERT KLAUS , SCHMUCK RAINER , SCHNEIDINGER BERND , SEIDEL CHRISTOPH , TISCHER WILHELM
IPC: C12N15/09 , C12P21/02 , A61K38/00 , A61P31/12 , A61P31/18 , C07K14/12 , C07K14/135 , C07K14/155 , C07K14/16 , C12N1/21 , C12N15/62
Abstract: Un proceso para la producción de un péptido antifusogénico como un péptido de fusión de una longitud de aproximadamente 14 a aproximadamente 70 aminoácidos en una célula huésped procariótica, que se caracteriza porque, en condiciones tal es que se formen cuerpos de inclusión de dicho péptido de fusión, a) en dicha célula huésped se expresa un ácido nucleico que codifica dicho péptido de fusión que consta de dicho péptido antifusogénico de una longitud de aproximadamente 10 a aproximadamente 50 aminoácidos unido por el extremo N-terminal a un péptido adicional de una longitud de alrededor de 4 a aproximadamente 30 aminoácidos; b) dicha célula huésped se hace crecer en cultivo; c) se forman dichos cuerpos de inclusión, se recuperan y se solubilizan; d) se aisla dicho péptido de fusión, y dicho péptido de fusión es representado por la Id. de Sec. Nº: 2, 11 o 12 y dicho péptido antifusogénico consiste en una secuencia de aminoácidos de Id. de Sec. Nº: 7, 9 o 10, o de un fragmento de la misma.
-
公开(公告)号：DK2017352T3
公开(公告)日：2014-12-01
申请号：DK08012856
申请日：2008-07-16
Applicant: HOFFMANN LA ROCHE
Inventor： STAIB ARNULF , MEIER THOMAS , MISCHLER REINHOLD , PESCHEL HARALD , HAJNSEK MARTIN
IPC: C12Q1/00
-
10.发明专利
公开(公告)号：MX2011008669A
公开(公告)日：2011-09-06
申请号：MX2011008669
申请日：2010-02-12
Applicant: HOFFMANN LA ROCHE
Inventor： MEIER THOMAS , SCHMUCK RAINER , HEINDL DIETER , HORN CARINA , GAESSLER-DIETSCHE CLAUDIA , HOENES JOACHIM
IPC: C12Q1/32
Abstract: La presente invención se refiere a un método para determinar un analito y a uno de sus elementos de diagnóstico adecuados.
-
-
-
-
-
-
-
-
-
Search Results
54
records
(took 0.023 seconds)
